Skip to main content

Waters' Fiscal Q2 Revenue Up 17 Percent as R&D Slides and Profit Jumps 25 Percent

NEW YORK (GenomeWeb News) — Waters today said its fiscal second-quarter revenue climbed 17 percent and its net income grew by 25 percent.
Total revenue for the three months ended June 30 rose to $353 million from $302 million year over year.
Waters CEO Douglas Berthiaume said the company’s “generally broad-based” first-quarter growth sped up in the second quarter, “with continued rapid uptake of our new products and strengthening demand from life science customers, including our large pharmaceutical accounts.”
Berthiaume also called the first half of 2007 “very encouraging.”
R&D spending slid 3 percent to $19.1 million from $19.7 million in the prior-year period.
Net income grew to $59.9 million from $47.8 million year over year.
As of June 30, Waters had $544.3 million in cash and cash equivalents.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.